The administration of Fetuin-A modulates the activity of BMPs and is likely to suppress the immediate cellular immune response of the joint, as it is described in clinical trials with Degenerative Joint Disease (DJD) (Xiao et al. 2013). The gene discussed is CLN5; the disease is osteoarthritis.